 |
|
Effect of hormone therapy on risk of heart disease may vary by age and years since menopause
April 04, 2007Additional analyses from the women's health initiative
WHAT: Secondary analyses of findings from the Women¡¦s Health Initiative (WHI) suggest that women who begin hormone therapy within 10 years of menopause may have less risk of coronary heart disease (CHD) due to hormone therapy than women farther from menopause. Overall, hormone therapy did not reduce the risk of CHD. However, the farther a woman was from the onset of menopause when she began hormone therapy, the greater her risk of CHD due to hormone therapy appeared to be. Although these findings did not meet statistical significance, they suggest that the health consequences of hormone therapy may vary by time from menopause.
These findings are consistent with the primary publications from the WHI trials of estrogen plus progestin and estrogen-alone (total of 27,347 participants) in showing no overall benefit for CHD, and in suggesting that risk due to hormones may differ depending on age or years since menopause.
"Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause," will be published in the April 4 issue of the Journal of the American Medical Association.
In a secondary analysis, scientists reanalyze previously collected data and findings in an effort to clarify or ask new questions. In the case of this latest WHI analysis, the authors combined the data from the two trials to explore in more detail the previously observed trends in hormone effects by distance from the menopause. Differences in hormone therapy effects were examined in three age categories (50 to 59, 60 to 69, and 70 to 79) or in years since the onset of menopause (less than 10, 10 to 19, and 20 or more). The Women's Health Initiative and the newly published analyses are funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health.
The analyses also suggest that the increased risk in heart disease due to hormone therapy in older women is primarily in those who also have hot flashes and night sweats. Study participants who had these symptoms were more likely to have risk factors for CHD such as high blood pressure or high blood cholesterol, but it was not clear whether this explained their higher risk on hormone therapy.
Other results from the analyses of the combined trials include:
- Confirmation that hormone therapy increases the risk of stroke and this risk does not appear to be influenced by age or time since menopause
- Even in women within 10 years of menopause, there appears to be an increased risk of breast cancer in women taking estrogen with a progestin
- There was a trend (not statistically significant) towards reduced risk for death associated with hormone use in younger compared to older women.
WHI is a major 15-year research program designed to address the most frequent causes of death, disability and poor quality of life in postmenopausal women — cardiovascular disease, cancer, and osteoporosis. Both the estrogen plus progestin and estrogen-alone trials of the WHI were stopped early because of increased health risks and the failure to prevent heart disease. Specifically, the estrogen plus progestin trial was stopped after 5.6 years because of an increased risk of breast cancer and because overall risks, including increased risks for heart attack, stroke, and blood clots, outnumbered benefits. The estrogen-alone study was stopped after 6.8 years because of an increased risk of stroke and no reduction in risk of CHD. The estrogen-alone study also found an increased risk of blood clots.
WHO: Jacques Rossouw, M.D. chief of the Women's Health Initiative Branch at NHLBI, and lead author of the study, is available to comment on the implications of the new study for women considering hormone therapy at different ages. He will note that the findings may be somewhat reassuring to younger women considering hormone therapy for short term relief of symptoms, but do not change the current recommendation that hormone therapy should not be used at any age for prevention of CHD. Women considering hormone therapy should have risk factors such as blood pressure and blood cholesterol measured and managed, and have regular mammograms. Dr. Rossouw can comment on the need for additional research to explore the overall findings and the finding regarding night sweats and hot flashes.
NIH/National Heart, Lung and Blood Institute
"Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause," will be published in the April 4 issue of the Journal of the American Medical Association.
In a secondary analysis, scientists reanalyze previously collected data and findings in an effort to clarify or ask new questions. In the case of this latest WHI analysis, the authors combined the data from the two trials to explore in more detail the previously observed trends in hormone effects by distance from the menopause. Differences in hormone therapy effects were examined in three age categories (50 to 59, 60 to 69, and 70 to 79) or in years since the onset of menopause (less than 10, 10 to 19, and 20 or more). The Women's Health Initiative and the newly published analyses are funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health.
The analyses also suggest that the increased risk in heart disease due to hormone therapy in older women is primarily in those who also have hot flashes and night sweats. Study participants who had these symptoms were more likely to have risk factors for CHD such as high blood pressure or high blood cholesterol, but it was not clear whether this explained their higher risk on hormone therapy.
Other results from the analyses of the combined trials include:
- Confirmation that hormone therapy increases the risk of stroke and this risk does not appear to be influenced by age or time since menopause
- Even in women within 10 years of menopause, there appears to be an increased risk of breast cancer in women taking estrogen with a progestin
- There was a trend (not statistically significant) towards reduced risk for death associated with hormone use in younger compared to older women.
WHI is a major 15-year research program designed to address the most frequent causes of death, disability and poor quality of life in postmenopausal women — cardiovascular disease, cancer, and osteoporosis. Both the estrogen plus progestin and estrogen-alone trials of the WHI were stopped early because of increased health risks and the failure to prevent heart disease. Specifically, the estrogen plus progestin trial was stopped after 5.6 years because of an increased risk of breast cancer and because overall risks, including increased risks for heart attack, stroke, and blood clots, outnumbered benefits. The estrogen-alone study was stopped after 6.8 years because of an increased risk of stroke and no reduction in risk of CHD. The estrogen-alone study also found an increased risk of blood clots.
WHO: Jacques Rossouw, M.D. chief of the Women's Health Initiative Branch at NHLBI, and lead author of the study, is available to comment on the implications of the new study for women considering hormone therapy at different ages. He will note that the findings may be somewhat reassuring to younger women considering hormone therapy for short term relief of symptoms, but do not change the current recommendation that hormone therapy should not be used at any age for prevention of CHD. Women considering hormone therapy should have risk factors such as blood pressure and blood cholesterol measured and managed, and have regular mammograms. Dr. Rossouw can comment on the need for additional research to explore the overall findings and the finding regarding night sweats and hot flashes.
NIH/National Heart, Lung and Blood Institute
Hormone Therapy Current Events and Hormone Therapy News RSSMenopause-cardiology consensus statement on cardiovascular disease and on HRT
A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT.
Scientists uncover new key to the puzzle of hormone therapy and breast cancer
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer.
Short-term hormone therapy and intermediate dose radiation increases survivial for early stage prostate cancer
Short-term hormone therapy given prior to and during intermediate dose radiation treatment for men with early stage prostate cancer increases their chance of living longer, compared to those who receive the same radiation alone.
Study shows hormone replacement therapy decreases mortality in younger postmenopausal woman
Hormone replacement therapy (HRT) to treat menopausal estrogen deficiency has been in widespread use for over 60 years. Several observational studies over the years showed that HRT use by younger postmenopausal women was associated with a significant reduction in total mortality; available evidence supported the routine use of HRT to increase longevity in postmenopausal women.
Hormone mix could cut breast cancer risk and treat symptoms of menopause
The right combination of estrogen and a selective estrogen receptor modulator (SERM), which blocks the effects of estrogen in breast tissue, could relieve menopause symptoms and cut breast cancer risk.
Breast tenderness during hormone replacement therapy linked to elevated cancer risk
Women who developed new-onset breast tenderness after starting estrogen plus progestin hormone replacement therapy were at significantly higher risk for developing breast cancer than women on the combination therapy who didn't experience such tenderness, according to a new UCLA study.
Women with breast cancer have low vitamin D levels
Women with breast cancer should be given high doses of vitamin D because a majority of them are likely to have low levels of vitamin D, which could contribute to decreased bone mass and greater risk of fractures, according to scientists at the University of Rochester Medical Center.
Researchers believe hormone therapy should not be stopped prior to mammograms
Researchers from Boston University School of Medicine (BUSM) are recommending that menopausal women on hormone therapy (HT) continue their treatment prior to having their annual mammogram screenings.
Prostate cancer patients on hormone therapy at increased risk for various heart diseases
New research has found that hormone therapy used to treat men with advanced prostate cancer is associated with an increased chance of developing various heart problems. Some choices of therapy appear, however, to be less risky than others.
Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.
More Hormone Therapy Current Events and Hormone Therapy News Articles
 |
The Miracle of Bio-Identical Hormones, 2nd edition by Michael E. Platt (Author) The 2nd edition of Dr. Platt's highly informative award-winning health book, The Miracle of Bio-Identical Hormones, How I Lost My Fatigue, Hot Flashes, ADHD, ADD, Fibromyalgia, PMS, Osteoporosis, Weight, Sexual Dysfunction, Anger, Migraines, provides many answers to common medical problems by explaining their underlying cause and how hormone balance brings you wellness. Outstanding praise for this reader-friendly book both nationally and internationally, because of its new ideas on hormone replacement and its unique perspective for optimum health. |
 |
Progesterone (Bio-Identical) Creme Plus Herbs - Fragrance Free/Unscented 8 oz. Pump Bottle by Radiant Laboratories - Made In USA Paraben-Free and Unscented. Replenish Your Progesterone Naturally and Safely. Don't suffer needessly with hot flashes and night sweats. Get your life back and feel good again. USP Progesterone from Wild Yam is Bio-identical to what is produced in the human body. The "Plus" is our Herbal Complex for Adrenal Gland Support. Feel Good Again! Hormone Replacement with Bio-Identical Hormones are Safe and Effective. WHY A CRÈME? Natural progesterone taken orally is mostly destroyed in the digestion process. Adequate absorption is only accomplished through topical application in a dermal delivery system. HAVE YOU EXPERIENCED ANY OF THESE SYMPTOMS? Migraines, Fatigue, Irritability, Cramping, Anxiety, Mood Swings, Depression, Fat Gain, Water Retention, Foggy Thinking, Breast Tenderness, Fibrocystic... |
 |
Postmenopausal Hormone Therapy: Weighing the Benefits and Risks (NCME Video 695) Also With: Leon Speroff (Primary Contributor), Network For Continuing Medical Education (Primary Contributor) |
![Grow Young with HGH: Naturally Raising Your HGH Levels with Ambient Sound Therapy [CD on Demand]](http://ecx.images-amazon.com/images/I/513XFWBliIL._SL160_.jpg) |
Grow Young with HGH: Naturally Raising Your HGH Levels with Ambient Sound Therapy [CD on Demand] by Dr. Jane Maati Smith C.Hyp. Msc.D. It is well know that HGH (Human Growth Hormone) is released during deep, Delta brainwave states, and that sound therapy and relaxation techniques can easily bring you down to the level of consciousness needed for the body to revitalize itself, and produce and release human growth hormone.The level of HGH produced diminishes with age; to increase the level of human growth hormone will bring about a youthening, with renewed muscle strength and vitality, increased bone mass and sexual performance, diminishing fat and wrinkles, improved blood pressure and cholesterol levels, and much more! This product is manufactured on demand using CD-R recordable media. Amazon.com's standard return policy will apply. |
|
Hormone Replacement Therapy: Addressing The Issues (NCME Video 849) Also With: Network for Continuing Medical Education (Primary Contributor), Gae Rodke (Primary Contributor) Hormone replacement therapy (HRT) has been available to women for decades. Although estrogen and progesterone formulations have changed over the years, the controversy surrounding the use of HRT has not. In the wake of recent data from landmark trials, including the Womens Health Initiative, physicians and patients are often left with questions concerning the relative benefits and risks of HRT. In this program, Dr. Gae Rodke offers an historical overview of HRT, along with a contemporary perspective on what the latest data mean for women considering HRT today. Using a case-presentation format, Dr. Rodke discusses key issues in the decision to recommend HRT for patients. Dr. Richard N. Pierson moderates the discussion and provides practical commentary. | |
 |
Emerita Menopause Plus Formula, Caplets, 60-Count Box by Emerita Dietary supplement. Peri/menopause support. Formulated with black cohosh. Contains no mineral oil, petroleum or animal anything. And our products are never tested on animals.(These statement have not been evaluated by the food and drug administration. This product and these statements are not intended to diagnose, treat, cure, or prevent any disease, but rather as a dietary supplement intended solely for nutritional support). Made in the USA. |
 |
Dr. John Lee's Hormone Balance Made Simple: The Essential How-to Guide to Symptoms, Dosage, Timing, and More by John R. Lee (Author), Virginia Hopkins (Author) The authors of the classice books on menopause andpremenopause bring women an easy-to-use guide on balancing hormonelevels safely and naturally |
 |
My Journey with Breast Cancer by Jo Ann Klein, MS, RN My journey with breast cancer from diagnosis to treatment to every day living. Must reading for the newly diagnosed.Kindle blogs are fully downloaded onto your Kindle so you can read them even when you're not wirelessly connected. And unlike RSS readers which often only provide headlines, blogs on Kindle give you full text content and images, and are updated wirelessly throughout the day. |
 |
ZMA-Primaforce Testosterone Boosting Formula , 360 Vegitarian Capsules (2 Pack) by Primaforce |
|
Low-dose estrogen boosts BMD in older women: small study.(Women's Health): An article from: Family Practice News by Heidi Splete (Author) This digital document is an article from Family Practice News, published by International Medical News Group on October 1, 2003. The length of the article is 540 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Low-dose estrogen boosts BMD in older women: small study.(Women's Health) Author: Heidi Splete Publication: Family Practice News (Magazine/Journal) Date: October 1, 2003 Publisher: International Medical News Group Volume: 33 Issue: 19 Page: 54(1) Distributed by Thomson... |
| © 2009 BrightSurf.com |